Figure 4.
Summary of the mechanism of LOC283070 in the development of CRPC. (a) RNA was extracted from the nucleus and cytoplasm. qRT-PCR detection of the relative expression of LOC283070 in the nucleus and cytoplasm. (b) The activity of AR was detected by luciferase activity assay in LNCaP cells with the overexpression of LOC283070 and PHB2, LOC283070 and pcDNA3.1, and pcDNA3.1 and PHB2 (n = 3, *P < 0.05). (c) Summary of the mechanism of LOC283070 in the transition of LNCaP cells into LNCaP-AI cells. PHB2: prohibitin 2; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; CRPC: castration-resistant prostate cancer; AR: androgen receptor; LNCaP-AI: androgen-independent LNCaP.